View Discovery

Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval Download PPT

Pre-Clinical (GLP)


Foundation for Neglected Disease Research
National Centre of Oceanic and Antarctic Research (NCAOR), Gao, India
GlaxoSmithKline, Bill & Melinda Gates Foundation
Institute of Materia Medica, CAMS & PUMC
Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
GlaxoSmithKline
Microbiotix, Inc.

Phase 1


GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation
TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc.
TB Alliance, Institute of Materia Medica
iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
Institute of Materia Medica, CAMS & PUMC

Phase 2


Shanghai Jiatan Biotech Ltd., subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China
University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University
PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute
Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research
Sequella, Inc
NIAID, NIH, DHHS, Bill & Melinda Gates Foundation, EDCTP